RCTs, historic partner of CERITD (Center for the Study and Research Intensification of Diabetes Treatment), has supported the development of DBLG1 ™ since 2011, a breakthrough innovation in the care of type 1 diabetics .

« The Lancet Digital Health » publishes the results of the SP7 clinical trial